FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * Yeaton Howard			2. Issuer Name and Ticker or Trading Symbol Akers Biosciences, Inc. [AKER]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O AKERS BIOSCIENCES, INC., 201 GROVE ROAD				3. Date of Earliest Transaction (Month/Day/Year) 12/28/2018						X Officer (give title below) Other (specify below) CEO, CFO			
(Street) THOROFARE, NJ 08086				4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(State)	(Zip)	Т	able I	- Non	-Deriv	vative S	Securities	Acqui	red. Dispe	osed of, or l	Beneficially (Owned	
Date	Date	2A. Deemed Execution Date, i	3. Transaction		etion	n 4. Securities Acquired		uired of (D)	d 5. Amount of Securities			6.	7. Nature of Indirect Beneficial
		(Month/Day/Year		ode	V	Amoun	(A) or (D)		(Instr. 3 a	nd 4)		or Indirect	Ownership (Instr. 4)
12/2	28/2018			A	,	7,500			7,500			D	
	Table II - I	Derivative Securi	ies Ac	•						OMB con	trol numbe	r.	
	(6	e.g., puts, calls, w	arran	ts, opt	ions,	conver	tible secur	rities)			1		
Transaction ate Month/Day/Year)	any	car) Code of Derivative Securities		eative rities ired rosed)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported	Owners Form of Derivati Security Direct (1 or Indirect)	Beneficia Ownershi (Instr. 4) O)	
							Expiration		Amount or				
3	First) ENCES, INC. Street) 2. Tr Date (Mor	First) (Middle) ENCES, INC., 201 Street) 2. Transaction Date (Month/Day/Year) 12/28/2018 Table II - I (a Transaction ate Month/Day/Year) 3A. Deemed Execution Date Execution Data	Akers Biosciet First) (Middle) ENCES, INC., 201 3. Date of Earlies 12/28/2018 Street) 4. If Amendment, 2086 State) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 12/28/2018 Table II - Derivative Securit (e.g., puts, calls, was a content of the content of	Akers Biosciences, First) (Middle) ENCES, INC., 201 Street) 4. If Amendment, Date 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 12/28/2018 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Execution Date, if any (Month/Day/Year) 3. Table I - Derivative Securities Action (e.g., puts, calls, warranter) Transaction Any (Month/Day/Year) (Month/Day/Year) (Instr. 8) To Derivative Securities Action (Instr. 8) Transaction Disponsory Ode (Instr. 8)	Akers Biosciences, Inc. First) (Middle) ENCES, INC., 201 3. Date of Earliest Transaction 12/28/2018 Street) 4. If Amendment, Date Origin 2086 State) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Instr. 8) Code 12/28/2018 A Table II - Derivative Securities Acquire (e.g., puts, calls, warrants, opton 20 of	Akers Biosciences, Inc. [AKI First) (Middle) ENCES, INC., 201 Street) 4. If Amendment, Date Original File (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Execution Date, if any (Month/Day/Year) 12/28/2018 A Table II - Derivative Securities Acquired, Distance (Linstr. 8) Transaction ate (Month/Day/Year) 3. Transaction Execution Date, if any (Month/Day/Year) Code V Table II - Derivative Securities Acquired, Distance (Linstr. 8) Transaction ate (Month/Day/Year) 3. Transaction Execution Date, if any (Month/Day/Year) Transaction ate (Month/Day/Year) A Transaction Date, if any (Month/Day/Year) (Month/Day/Year) (Instr. 8) Transaction Date, if Code (Instr. 8) Transaction Date, if Code (Instr. 8) Transaction Date, if Derivative Securities Acquired (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	Akers Biosciences, Inc. [AKER] First) (Middle) ENCES, INC., 201 3. Date of Earliest Transaction (Month/Day 12/28/2018 4. If Amendment, Date Original Filed(Month 12/28/2018 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Execution Date, if (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Execution Date, if (Instr. 3) Code V Amount 12/28/2018 A 7,500 Table II - Derivative Securities Acquired, Disposed (e.g., puts, calls, warrants, options, converting any (Month/Day/Year) Transaction ate Execution Date, if any (Month/Day/Year) Transaction ate (Instr. 8) Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 8) [Instr. 8] Persons where the form distributed in the form distributed	Akers Biosciences, Inc. [AKER] First) (Middle) (BNCES, INC., 201) 3. Date of Earliest Transaction (Month/Day/Year) 12/28/2018 4. If Amendment, Date Original Filed(Month/Day/Year) 2/28/2018 Table I - Non-Derivative Securities Acq Code (A) or Disposed of (Instr. 8) (Instr. 3, 4 and 5) (Instr. 3, 4 and 5) (Instr. 3, 4 and 5) (Instr. 3) (A) or Disposed of (D) (Instr. 8) (Instr. 3) (Akers Biosciences, Inc. [AKER] First) (Middle) ENCES, INC., 201 3. Date of Earliest Transaction (Month/Day/Year) 12/28/2018 4. If Amendment, Date Original Filed(Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction (Month/Day/Year) 4. Transaction Date (Month/Day/Year) 3. Transaction (Month/Day/Year) 4. Transaction Date (Month/Day/Year) 3. Transaction (A) or Disposed of (D) Date Code (A) or Disposed of, or Beneficiall (Month/Day/Year) Date (Month/Day/Year) 1. Date Code (Month/Day/Year) Date (Month/Day/Year) Date Code (Month/Day/Year) Date C	Akers Biosciences, Inc. [AKER] Akers Biosciences, Inc. [AKER]	Akers Biosciences, Inc. [AKER] Akers Biosciences, Inc. [AKER] Director	Akers Biosciences, Inc. [AKER] Check all applic Director X Officer (give title below) ENCES, INC., 201 12/28/2018 4. If Amendment, Date Original Filed(Month/Day/Year) 1086 Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned (Instr. 3, 4 and 5) (Month/Day/Year) 12/28/2018 A 7,500 A 5 1.27 Transaction arrate line for each class of securities beneficially owned directly or indirectly. Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3 and 4) Persons who respond to the collection of information contained in this form are not required to respond unlet the form displays a currently valid OMB control number (Instr. 5) Transaction are found in this form are not required to respond unlet the form displays a currently valid OMB control number (Instr. 5) Transaction are found in this form are not required to respond unlet the form displays a currently valid OMB control number (Instr. 5) Transaction are found in this form are not required to respond unlet the form displays a currently valid OMB control number (Instr. 5) Transaction are found in this form are not required to respond unlet the form displays a currently valid OMB control number (Instr. 5) Transaction are found in this form are not required to respond unlet the form displays a currently valid OMB control number (Instr. 5) Transaction are found in this form are not required to respond unlet the form displays a currently valid OMB control number (Instr. 5) Transaction are found in this form are not required to respond unlet the form displays a currently valid OMB control number (Instr. 5) Transaction are found in this form are not required to respond unlet the form displays a currently valid OMB control number (Instr. 5) Transaction are found in this form are not required to respond unlet the form displays a currently valid OMB control number (Instr. 5) Transaction are found in this form are not required to respond unlet the form displays a currently valid OMB control number (Instr. 5)	Akers Biosciences, Inc. [AKER] Akers Biosciences, Inc. [AKER] Check all applicable) 10% owner 10% owner

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Yeaton Howard C/O AKERS BIOSCIENCES, INC. 201 GROVE ROAD THOROFARE, NJ 08086			CEO, CFO			

Signatures

/s/ Howard R. Yeaton	01/02/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.